Opendata, web and dolomites

MolPredict

Neural-based solution to boost drug preclinical research success

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MolPredict" data sheet

The following table provides information about the project.

Coordinator
PHARMACELERA SL 

Organization address
address: CL ESTEVE PILA NUM, 11 P.1 PTA.1
city: SAINT CUGAT DEL VALLES BARCELONA
postcode: 8173
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://www.pharmacelera.com/uncategorized/pharmacelera-participates-in-the-sme-instrument-phase-i-program/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PHARMACELERA SL ES (SAINT CUGAT DEL VALLES BARCELONA) coordinator 50˙000.00

Map

 Project objective

The competitiveness of the R&D process in this industry has been steadily declining during the past two decades. Whereas in 2000 the average cost for developing a new drug was close to €1 billion, in 2015 the estimated cost was €2.58 billion, a 150% increase. Consequently, the different actors of the pharmaceutical R&D industry have an urgent need to improve their effectiveness to develop new drugs. In this sense, the early stage of the R&D process shows the greatest potential to increase the success rate of new drug candidates, as it is in this phase where candidate molecules are selected for further testing in humans. Computer Aided Drug Design (CADD) is the most cost-effective tool for drug discovery. These technologies allow researchers to screen large databases of molecules and simulate its interaction in vivo. However, they are extremely intensive in computational resources. As a result, existing solutions have to implement simplifications in the simulations in order to incur acceptable computational times. These simplifications come at the cost of accuracy, finding a low rate of bioactive molecules that, in addition, usually fail during clinical trials. Pharmacelera aims at creating a new computing standard for Computer-Aided Drug Design (CADD) through an open machine learning platform that enables accurate prediction of molecular properties of candidate molecules based on quantum-mechanics (QM) calculations during drug development. By providing early stage ADME-Tox analysis, thus dramatically reducing the failure rate of the drug design process. In addition, by combining HPC, new disruptive molecular modelling techniques (computational chemistry) and machine learning, PharmAgile will be 20x faster and 10x more precise than any existing solution. Consequently, PharmAgile will be able to reduce the overall costs of drug development by up to 19% and the drug development time up to 8%. This translates into $335 million and 2 years saved per new approved drug.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOLPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOLPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More  

SCAT (2019)

Smart Composites for Additive Technology

Read More